Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,003 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Platelets Clear all
Withdrawn No phase listed Observational

Case Series on Using Bone Marrow Concentrate for Alar Ligament Injuries

NCT03557606
View directory record Official record
Conditions
Craniocervical Injuries
Interventions
Alar treatment with BMC using anterior approach
Procedure
Lead sponsor
Regenexx, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Broomfield, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 29, 2026, 10:06 PM EDT
Not listed No phase listed Observational

Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia

NCT03288441
View directory record Official record
Conditions
Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
Interventions
Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug, Change platelet transfusion threshold, Full dose antithrombotics, Mechanical measures, Intermediate dose antithrombotic
Drug · Biological · Device
Lead sponsor
Maastricht University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 29, 2026, 10:06 PM EDT
Not listed Phase 1 Interventional

Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

NCT01175109
View directory record Official record
Conditions
Chordoma
Interventions
Imatinib + LBH589
Drug
Lead sponsor
Deric M Park MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 29, 2026, 10:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

NCT01656252
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 29, 2026, 10:06 PM EDT
Not listed Early Phase 1 Interventional

Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater Trochanteric Pain Syndrome

NCT02031367
View directory record Official record
Conditions
Greater Trochanteric Pain Syndrome
Interventions
Triamcinolone Acetonide, Platelet Rich Plasma
Drug · Other
Lead sponsor
C.R.Darnall Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Fort Hood, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 29, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Botulinum-assisted Orbital Fat Augmentation With PRP (Platelet-rich-plasma)

NCT02244671
View directory record Official record
Conditions
Orbital Atrophy
Interventions
fat, PRP, botulinum toxin, botulinum toxin, PRP
Procedure · Drug · Device
Lead sponsor
Fox, Donald Munro, M.D., P.C.
Individual
Eligibility
21 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 29, 2026, 10:06 PM EDT
Active, not recruiting Phase 2 Interventional

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

NCT00044304
View directory record Official record
Conditions
Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome
Interventions
Imatinib, Ruxolitinib
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 29, 2026, 10:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction

NCT01915407
View directory record Official record
Conditions
Platelet Dysfunction Due to Aspirin Ingestion
Interventions
Not listed
Lead sponsor
Aggredyne, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 29, 2026, 10:06 PM EDT
Completed No phase listed Observational

Platelet Products Tested With the ThromboLUX® Platelet Quality Test

NCT02158416
View directory record Official record
Conditions
Poor Platelet Transfusion Outcome
Interventions
Not listed
Lead sponsor
LightIntegra Technology
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 29, 2026, 10:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Aortic Stenosis - B.A.S.S.

NCT01334801
View directory record Official record
Conditions
Aortic Stenosis, Disorder of Prosthetic Cardiac Valve, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Hypertrophic Cardiomyopathy, Tricuspid Valve Insufficiency
Interventions
Blood Draw
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 29, 2026, 10:06 PM EDT
Not listed Phase 4 Interventional

Implementing Precision Medicine Approaches to Guide Anti-platelet Selection

NCT04090281
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI, Unstable Angina (UA)
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 29, 2026, 10:06 PM EDT
Completed Not applicable Interventional Results available

Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing

NCT01639144
View directory record Official record
Conditions
Elective Foot and Ankle Surgery.
Interventions
PRP and PPP
Biological
Lead sponsor
Gary M. Kiebzak, Ph.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 29, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL

NCT00732498
View directory record Official record
Conditions
Lymphoma
Interventions
Methylprednisolone, Etoposide, Cytarabine, Cisplatin, Rituximab, In-Zevalin, Y-Zevalin
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 29, 2026, 10:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones

NCT00556400
View directory record Official record
Conditions
Aplastic Anemia, Menorrhagia, Amenorrhea
Interventions
Lo-Ovral Oral Contraceptive Pills, Placebo - sugar pill
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 55 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 29, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

NCT01340651
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Winter Park, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 29, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Results available

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

NCT01317875
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
3
States / cities
Winter Park, Florida • Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 29, 2026, 10:06 PM EDT
Not listed Phase 4 Interventional

Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin

NCT00370045
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Bivalirudin with and without eptifibatide
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2006 · Synced Oct 29, 2026, 10:06 PM EDT
Recruiting No phase listed Observational

Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear

NCT03909139
View directory record Official record
Conditions
Acetabular Labrum Tear, Femoro Acetabular Impingement, Chondral Defect, Bone Marrow Aspirate Concentrate, Mesenchymal Stromal Cell
Interventions
BMAC
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 29, 2026, 10:06 PM EDT
Completed Phase 3 Interventional

Trauma Resuscitation With Low-Titer Group O Whole Blood or Products

NCT05638581
View directory record Official record
Conditions
Wounds and Injuries, Shock, Hemorrhagic
Interventions
LTOWB, Components
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 29, 2026, 10:06 PM EDT
Completed Not applicable Interventional Results available

COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT

NCT01925794
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
COBRA PzF
Device
Lead sponsor
CeloNova BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
22
States / cities
Bakersfield, California • Miami Beach, Florida • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 29, 2026, 10:06 PM EDT
Not listed Phase 1 Interventional

A Comparison of PRP Treatment to the IA vs. IA and EA Environments in Patients Diagnosed With Hip Osteoarthritis

NCT04241354
View directory record Official record
Conditions
Osteoarthritis, Hip, Osteoarthritis, Degeneration
Interventions
Leukocyte-poor platelet rich plasma
Biological
Lead sponsor
Regenerative Orthopedics and Sports Medicine
Industry
Eligibility
30 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
North Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 29, 2026, 10:06 PM EDT
Active, not recruiting Not applicable Interventional

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

NCT07597239
View directory record Official record
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 10:06 PM EDT
Recruiting Phase 3 Interventional

Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies

NCT06003101
View directory record Official record
Conditions
Acetabular Labrum Tear, Femoro Acetabular Impingement, Chondral Defect, Bone Marrow Aspirate Concentrate
Interventions
Bone marrow aspirate concentrate (BMAC), Control
Biological · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2045
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 29, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

Preliminary Testing of New Treatment for Chronic Leg Wounds

NCT00000431
View directory record Official record
Conditions
Varicose Ulcer
Interventions
PDGF-B/Ad5
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 29, 2026, 10:06 PM EDT